SMEAL WIKI

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma

Alan Chan, Carolyn Dang, J. Wiśniewski, Xiuhua Weng, Edward Hynson, Lixian Zhong, Leslie Wilson
Year2022
VenueAmerican Journal of Clinical Oncology
Typearticle
Citations10
DOI10.1097/coc.0000000000000884
OpenAlexW4205821319

Topics

Renal cell carcinoma treatmentNivolumabMedicineIpilimumabAxitinibPembrolizumab